Real‐world Omalizumab and Mepolizumab treated difficult asthma phenotypes and their clinical outcomes-Reference-Cited by-同舟云学术

Real‐world Omalizumab and Mepolizumab treated difficult asthma phenotypes and their clinical outcomes

Published:2021-05-06 Issue:8 Volume:51 Page:1019-1032
ISSN:0954-7894
Container-title:Clinical & Experimental Allergy
language:en
Short-container-title:Clin Experimental Allergy

Author:

Fong Wei Chern Gavin¹²^ORCID,Azim Adnan²³^ORCID,Knight Deborah³,Mistry Heena¹²³,Freeman Anna²³,Felongco Mae²³,Kyyaly Aref¹²³,Harvey Matthew³,Dennison Patrick³,Zhang Hongmei⁴^ORCID,Howarth Peter²³,Arshad Syed Hasan¹²³,Kurukulaaratchy Ramesh J.¹²³

Affiliation:

1. David Hide Asthma and Allergy Research CentreIsle of Wight UK

2. Clinical and Experimental Sciences Faculty of Medicine University of Southampton Southampton UK

3. NIHR Southampton Biomedical Research Centre University Hospitals Southampton NHS Foundation Trust Southampton

4. Division of Epidemiology Biostatistics, and Environmental Health School of Public Health University of Memphis Memphis TN USA

Funder

Novartis

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cea.13882

Reference41 articles.

1. Asthma phenotypes and the use of biologic medications in asthma and allergic disease: The next steps toward personalized care

2. BTS/SIGN.British guideline for the management of asthma SIGN 158 July 2019.https://www.brit‐thoracic.org.uk/quality‐improvement/guidelines/asthma/. Accessed January 21 2021.

3. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma

4. Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma

5. Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Psychopathology in asthma patients: analysis of demographic and clinical associations;Journal of Asthma;2024-09-09

2. Clinical Response Predictive Model for Omalizumab in Moderate-to-Severe Asthma Patients;International Journal of Clinical Practice;2024-05-04

3. Mepolizumab in Patients With Severe Asthma and Comorbidities: 1-Year REALITI-A Analysis;The Journal of Allergy and Clinical Immunology: In Practice;2023-12

4. Long-Term Real-World Outcomes of Mepolizumab and Benralizumab Among Biologic-Naive Patients With Severe Eosinophilic Asthma: Experience of 3 Years’ Therapy;The Journal of Allergy and Clinical Immunology: In Practice;2023-09

5. Comprehensive Characterization of Difficult-to-Treat Asthma Reveals Near Absence of T2-Low Status;The Journal of Allergy and Clinical Immunology: In Practice;2023-09